Denali Therapeutics Inc (NASDAQ:DNLI) Shares Purchased by Gilder Gagnon Howe & Co. LLC

Share on StockTwits

Gilder Gagnon Howe & Co. LLC increased its holdings in shares of Denali Therapeutics Inc (NASDAQ:DNLI) by 3.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,385,233 shares of the company’s stock after purchasing an additional 124,211 shares during the quarter. Gilder Gagnon Howe & Co. LLC owned 3.19% of Denali Therapeutics worth $81,855,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Mark Asset Management LP increased its position in shares of Denali Therapeutics by 11.1% during the 2nd quarter. Mark Asset Management LP now owns 180,498 shares of the company’s stock worth $4,364,000 after purchasing an additional 17,976 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Denali Therapeutics by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 7,085,930 shares of the company’s stock worth $171,337,000 after purchasing an additional 177,599 shares during the last quarter. Advisory Research Inc. increased its position in shares of Denali Therapeutics by 56.2% during the 2nd quarter. Advisory Research Inc. now owns 37,136 shares of the company’s stock worth $898,000 after purchasing an additional 13,360 shares during the last quarter. TD Asset Management Inc. increased its position in shares of Denali Therapeutics by 76.1% during the 2nd quarter. TD Asset Management Inc. now owns 57,607 shares of the company’s stock worth $1,393,000 after purchasing an additional 24,900 shares during the last quarter. Finally, Federated Hermes Inc. acquired a new stake in shares of Denali Therapeutics during the 2nd quarter worth about $6,709,000. 77.91% of the stock is owned by hedge funds and other institutional investors.

In related news, major shareholder Douglas K. Bratton sold 90,056 shares of the company’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $24.78, for a total transaction of $2,231,587.68. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Marc Tessier-Lavigne sold 400,000 shares of the company’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $26.10, for a total value of $10,440,000.00. Following the transaction, the director now directly owns 2,739,043 shares in the company, valued at approximately $71,489,022.30. The disclosure for this sale can be found here. In the last three months, insiders sold 839,631 shares of company stock worth $21,133,146. Corporate insiders own 19.30% of the company’s stock.

Several equities analysts have weighed in on DNLI shares. ValuEngine downgraded Denali Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, September 1st. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 target price (up from $28.00) on shares of Denali Therapeutics in a research report on Thursday, August 20th. BidaskClub downgraded Denali Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday. TheStreet raised Denali Therapeutics from a “d+” rating to a “c-” rating in a research report on Wednesday, May 20th. Finally, Nomura reaffirmed a “buy” rating and issued a $35.00 target price on shares of Denali Therapeutics in a research report on Wednesday, May 13th. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $33.20.

Shares of DNLI traded down $0.04 during midday trading on Friday, hitting $30.86. The company had a trading volume of 450,713 shares, compared to its average volume of 751,424. The firm has a market capitalization of $3.27 billion, a P/E ratio of -14.35 and a beta of 1.91. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.57 and a current ratio of 9.57. The company’s 50-day simple moving average is $28.82 and its 200-day simple moving average is $24.05. Denali Therapeutics Inc has a 1 year low of $12.39 and a 1 year high of $35.70.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Friday, August 7th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.61) by $0.05. Denali Therapeutics had a negative return on equity of 45.90% and a negative net margin of 778.32%. Equities analysts predict that Denali Therapeutics Inc will post 1.4 earnings per share for the current fiscal year.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Recommended Story: Calculating net profit and net profit margin ratio

Institutional Ownership by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply